Association Of
Nuclear Medicine Physicians Of India
ANMPI News
ANMPI News
Date : 29-05-2021
Time :
Location :
Remembering Prof (Dr.) Arun Malhotra (14 Nov 1948 – 26 May 2021) “A Noble Soul Who Lived A Life for Generations to Come” Prof (Dr.) Arun Malhotra was a man of his word and ambitions who carved the future for generations to come. In him, we see a father, mentor, colleague, leader who envisioned and uplifted the future of Nuclear Medicine in the country, right from its nascent stage. He developed the Nuclear Medicine department of All India Institute of Medical Sciences, New Delhi to unprecedented heights, but his contributions do not end there. He was instrumental in promoting and developing the specialty all over the country; from west to east, north to south. His well cultured acumen and down to earth personality still echoes in everyone’s hearts. And it will be; forever an undying treasure we all are proud of. From research to patient care; from academics to socialization, his presence was always scintillating and will be greatly missed. He was the nidus for harmony of the Nuclear Medicine specialty in the country. He preached not to be afraid of challenges, but take them as stepping stones to success. And yet, he was more than a just a sublime professional. He was a loving husband, caring father and a noble human. His sense of humor, ever smiling face full of joy and warm-hearted down to earth nature made one immediately fall in sync to his rhythms. His soft-spoken words lit up every social gathering. He was the center of all the fond memories and celebrations we had. He celebrated life; he was the celebration! A humble, soft-spoken, noble and caring soul lived a lifetime; a lifetime to be remembered for generations to come. An irreplaceable loss! an end of an era! And yet, there is still Prof (Dr.) Arun Malhotra deep inside our hearts. Not many can do this. Thank you, Sir! [Dept of Nuclear Medicine, AIIMS, Delhi]
Date : 13-12-2020
Time :
Location :
68Ga-pentixafor, which targets the CXCR4 biomarker involved in the growth, survival and dissemination of aggressive B-cell lymphoma, has been demonstrated as an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma. In a retrospective, proof of concept analysis, 11 patients were imaged with 68Ga-pentixafor PET (four with PET/computed tomography and seven with PET/MRI). Lesions were analyzed, and immunohistochemistry was conducted. The CXCR4-directed PET imaging with 68Ga-pentixafor was found to be positive in all active CNS lymphoma lesions, with a high tumor-to-background ratio that offered exceptional contrast, thus demonstrating its potential for risk stratification and response assessment.
Date : 19-12-2020
Time :
Location :
The U.S. Food and Drug Administration's (FDA) approval of 68Ga PSMA-11 PET for evaluation of prostate cancer sets a precedent for academic research. The agency's action marks a unique approach to simultaneous new drug application (NDA) approvals and opens the door for wider clinical use of the imaging technique. "The FDA has never approved two institutions' two NDAs at the same time," said Dr. Thomas Hope, associate professor in residence at UCSF. "The fact that the FDA was so understanding and flexible to allow this is what encouraged and enabled an academic collaboration like this. It is a unique process and infrequently does anything like this ever happen in academia."
Date : 20-12-2020
Time :
Location :
Recordings of the the ANMPI lectures and the ANMPI annual conference presentations are now being made available on the website. Please visit the Webinars section below to access the same. All recordings (which have been approved by the speakers for sharing in public domain) will be available in the archives section. Few of the initial recordings are in need of extensive editing as that was the period when we were figuring out the online classes and there were many glitches/disturbances. However we will definitely try to salvage all recordings and make them available online. - Web Co-Ordinator ANMPI